Research programme: ocular therapeutics - OccuRxAlternative Names: OCX-063
Latest Information Update: 30 Jun 2015
At a glance
- Originator OccuRx
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic retinopathy
Most Recent Events
- 18 May 2015 Preclinical trials in Diabetic retinopathy in Australia (unspecified route)